Good day, ladies and gentlemen, and welcome to the Consensus Q3 2023 earnings call. My name is Paul, and I will be the operator assisting you today. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. On this call from Consensus will be Scott Turicchi, CEO, John Nebergall, COO, Jim Malone, CFO, and Adam Varon, Senior Vice President of Finance. I will now turn the call over to Adam Varon, Senior Vice President of Finance at Consensus. Thank you. You may begin. Good afternoon, and welcome to the Consensus investor call to discuss our Q3 2023 financial results, other key information, and 2023 guidance. Joining me today are Scott Turicchi, CEO, John Nebergall, COO, and Jim Malone, CFO. The earnings call will begin with Scott providing opening remarks. John will give you an update on our operational progress since our Q2 investor call, and then Jim will discuss the Q3 2023 financial results and 2023 guidance. After we finish our prepared remarks, we will conduct a Q&A session. At that time, the operator will instruct you on the procedures for asking your question. Before we begin our prepared remarks, allow me to direct you to the safe harbor language on slide 2. As you know, this call and the webcast will include forward-looking statements. Such statements may involve risks and uncertainties that would cause actual results to differ materially from the anticipated results. Some of those risks and uncertainties include, but are not limited to, the risk factors outlined on slide three that we have disclosed in our 10-K SEC filing, as well as a summary of those risk factors that we have included as part of the slideshow for the webcast. We refer you to discussions in those documents regarding safe harbor language, as well as forward-looking statements. Now, let me turn the call over to Scott. Thank you, Adam. It's now been two years since our spin, and I would like to make some brief comments as we look back over these past two years. As you know, we spun with a go-to-market focus and product roadmap aimed at the healthcare sector. We've made substantial investments and strides in this space, with more than half of our corporate revenue now coming from the healthcare sector. However, we have also seen inflation and a tight labor market impact revenue growth in this piece of our business. In fact, in the past two quarters, we have seen overall corporate revenue growth of approximately 3%, down from approximately 13% in Q3 of 2022. This is driven by a slowdown in revenue generation from our healthcare customers due to stable usage, slower sign-ups, and a slow ramp of our larger customers. Until there is a substantial relief in the labor markets, we expect these trends to continue. As we look to next year with continuing uncertainty in both the economy as well as the labor markets, we'll be focusing our attention on EBITDA and free cash flow generation. As a result, we will reduce our capitalized investments from the level of the past two years, while still investing in the business at a rate higher than prior to the spin. The record cash balances of $156 million in future free cash flow will be dedicated to repurchasing our equity and debt securities. Now that we have cleared the two-year mark from the spin, we are able to repurchase debt, and as a result, the board has authorized a $300 million repurchase program over the next three years. This program covers both the 6% notes that mature in October 2026, as well as the 6.5% notes due in October 2028. These repurchases can take a variety of forms and will be opportunistic, similar in manner to our existing stock repurchase program. While we are early in the budgeting process, I would expect negligible overall revenue growth in 2024, with continuing decline in SOHO revenues offset by mid-single-digit growth in our corporate channel. I would also expect greater growth in our EBITDA than in our revenue. We will be providing full year 2024 guidance on our Q4 earnings call to be held in February. While our revenues were disappointing in the quarter, there were several factors that affected the results. Within the SOHO channel, we cut a meaningful amount of marketing spend on questionable profitability channels. I would also note that as we discussed last quarter, the price change to that base is complete. On the corporate side, in addition to the headwinds experienced in the healthcare sector, we also completed the migration of our FaxBox customer base, but did incur customer attrition in the process. This was a legacy system that needed to be retired, notwithstanding the customer and revenue loss. On the bright side, our EBITDA margin remained strong at 52.5%, the midpoint of our range, and coupled with interest income on our cash balances and a lower share count, produced year-over-year growth in EPS. In addition, we generated a record $50 million of free cash flow for a full fiscal quarter post-spin, and more importantly, $83 million for the nine months. As usual, there are timing differences in payment of estimated taxes and cash collections of receivables. Also, as we have noted before, due to our debt structure and interest payments, we generate most of our free cash flow in quarters one and three. I will now turn the call over to John for more detail on the quarter. Hey, thank you, Scott. As we mentioned on the last call, we held a meeting with the ECFax partners to discuss tactics for accelerating the rollout. The talks were substantive, and all partners agreed that an acceleration of the overall program in 2024 would be a mutual goal. In that context, we are actively working on acceleration options and are making progress on the overall plan. ... While not final, we are encouraged by the direction and anticipate a favorable schedule for next year. Now, that said, we have seen the hurdles that can be encountered in a project of this scope, and are going to be cautious in forecasting any revenue expected from the program next year. As for the current state of the implementation, we have increased the numbers of facilities using ECFax, and while the pure number of facilities is an improvement, the level of usage per facility varies, and not every location has been fully implemented. As we have discussed, there are nearly 30 other government agencies in the pipeline, and while progress is being made, the threat of a government shutdown earlier this quarter and the upcoming holiday season have slowed the speed of discussions. We do not expect any measurable progress on this front until sometime in 2024. On the Clarity front, we are in the process of implementing our first Clarity PA client, who signed last July. Clarity PA is a specifically engineered version of Clarity aimed at the problem of prior authorization workflow. As Scott has mentioned, the slow progress in both closing the deal and implementing the customers are fully on display here. The deal took 15 months to close and will likely require an additional 12 months to implement. In the AI market, this is a typical timeframe and is what we can anticipate with each subsequent prospect engagement. Separately, we have launched the Clarity CD product, tuned for clinical documentation administration and built a pipeline of interest. Our sales team is progressing through those opportunities, and serious discussions are underway. On the sales front for the quarter, Q3 bookings came in at $6.4 million, which was a welcome improvement from both Q1 and Q2 results. Historically, Q3 has been the best month seasonally for sales, and it appears to be holding true this year. While this result is a welcome improvement sequentially, it is still under last year's Q3 result, and year to date, overall, 2023 bookings are still lagging 20% behind our 2022 pace. Our advanced product sales came in just short of $1 million, and while that was an improvement over Q2, that also still lags behind the 2022 pace. We've also continued our aggressive pursuit of harvesting healthcare accounts from the SOHO base into a more expensive corporate product. For the past several quarters, we have been successfully upgrading more than 1,000 SOHO accounts per quarter into a corporate product, and this quarter is no exception, with about 1,300 customers upgraded from SOHO. While each upgrade is a positive increase in revenue, it does come with a negative impact in a couple of key metrics that are important to note. First, these customers tend to be on the extreme low end of our corporate average revenue per account, or ARPA range, impacting our overall corporate ARPA with downward pressure. Second, the process for changing an account from SOHO to corporate includes cancellation of the SOHO account. This process then creates an unfavorable impact on SOHO churn, as our system calculates the cancellation as a churned account. So as you assess our operating metrics, be aware that our upgrade program has those impacts. In the quarter, we were able to close two large hospital system deals with a combined 60+ hospitals, over 400 clinics, and more than 100 skilled nursing facilities. Due to their level of complexity, we anticipate that implementation will take most, if not all, of 2024. As you will recall from our discussion about the go-to-market realignment earlier this year, we established the e-commerce group for all web-based self-service sales. This group includes our traditional SOHO revenue stream and has been expanded to encompass upmarket sales to the SMB market. This quarter, the SOHO market saw a further moderation of the churn that we saw last year due to our price increase rollout. Churn for the quarter came in just under 3.5%, a nice improvement from last year's Q3 result. Now, as mentioned earlier, that number includes the 1,300 accounts that we upgraded to corporate. As we discussed last call, we continue to see the pace of new adds fall under pre-pandemic levels. As we've also said on our last call, the expectation is that this trend will be the new normal in SOHO as we have made the decision to pull back spending in areas of SOHO that we found to have questionable profitability. And we'll continue to scrutinize our marketing spend to ensure high returns for the business. This quarter, we launched an e-commerce product targeting SMB customers. Traditionally, we had used our inside sales team to sell inbound web opportunities, and these form fill customers would be assisted by a live sales rep. The release of this eFax Protect product marks our first entry into the self-service sales approach for corporate. Finally, on the product front, as mentioned earlier, we successfully released Clarity CD, and we have also successfully completed the jSign HITRUST audit. Now let me pass the presentation to Jim Malone, our CFO. Jim? Thank you, John, and good afternoon, everyone. Let's start with our corporate business results. Q3 2023 revenue was $50.4 million, an increase of $1.5 million, or 3% over the prior year comparable period, versus growth of 13% from Q3 2021- Q3 2022. The corporate revenue growth slowed to 3% from 13% in Q3 2022, due to an increased number of customers at lower ARPS, as our large, as our larger clients remain slow in both their decision cycles and implementation. Corporate ARPA, $312, was down $36 or 10.5% from the prior year, attributable to the mix of paid ads at a lower ARPA, including SOHO accounts moving to corporate. However, it was similar to the ARPA as we experienced in Q2. Monthly churn improved 20 basis points to 1.5% over the prior year, delivering a trailing 12-month revenue retention of 100%. Moving to SOHO results. Q3 2023, revenue of $40.1 million, a decrease of $2.7 million, or 6.2% over the prior comparable period. This decrease was driven by an anticipated decline in our base, offset by the impact of price increases in the period. This was the hardest comparable, as the price increase had substantial effect in Q3 2022, but there had not yet been a meaningful increase in churn. In addition, as Scott noted, we cut marketing spend, where the lifetime value to customer acquisition cost was marginally profitable. The ARPA of $15.31 increased by $0.89 or approximately 6% year-over-year, benefiting from the price increase. Churn declined 10 basis points to 3.5% compared to the prior period and pre-price increase levels. Notwithstanding the above 6.2 revenue decline in the quarter, the full year SOHO revenue decline is benefiting from the first half performance of a negative 3% and expected to improve ending the year within our 2%-4% guidance range. Moving to Q3 consolidated results. Revenue of $90.6 million is a decrease of $1.2 million or 1.3% over Q3 2022. Adjusted EBITDA of $47.5 million was a decrease of $1.6 million over Q3 2022 or 3.2%, delivering a 52.5% margin. The main drivers are the revenue flow through mentioned above, the planned employment costs, timing of bad debt expenses, while managing costs to keep EBITDA margins within the 50%-55% guidance expectations. The Q3 2023 non-GAAP tax rate and share count was 19.1% and 19.7 million shares, respectively. Note: We repurchased 152,000 shares in the quarter and approximately 500,000 shares year to date. Adjusted non-GAAP net income, $29.7 million, increased $1.1 million, or 3.7%, driven by the benefits of interest income of $1.5 million, non-cash revaluation of intercompany accounts of $0.7 million, and a lower effective tax rate. Non-GAAP EPS of $1.51 was better than the prior comparable year by 5.6% or $0.08. We continued to build our cash position, ending the quarter with a record $156 million in cash and cash equivalents, which is sufficient to fund our operations and debt. Q3 was a record post-spin full fiscal quarter free cash flow of $49.9 million. Turning to guidance, Q4 2023 guidance range is as follows: revenues between $87.5 million and $90.5 million, with $89 million at midpoint. Adjusted non-GAAP EBITDA between $46.3 million and $48.2 million, with $47.4 million at midpoint. Adjusted non-GAAP EPS at $1.15-$1.19, with $1.17 at midpoint. For the full year, the guidance is revenues between $362 million and $365 million, with $364 million at midpoint. Adjusted non-GAAP EBITDA between $186 million and $188 million, with $187 million at the midpoint. Adjusted non-GAAP EPS at $5.13-$5.17, with $5.15 at the midpoint. We're planning to file our Q3 2023 10-Q at market close today, November ninth. That concludes my formal comments. I'd like to turn the call back to Scott for some final remarks before we move to the Q&A section. Thank you. Thank you, Jim. Before we begin our Q&A session, I would like to take the opportunity to talk about a management transition noted in our press release. John Nebergall, our Chief Operating Officer, will step down from this position effective December 31. John will continue as a strategic advisor in 2024 as he relocates and travels the world. I want to thank John for his more than 5 years of service to the business. He was hired in mid-2018 to grow the business, focus the opportunity on the healthcare sector, and build out our management team. As part of that build-out, he hired Johnny Hecker, who will become our Chief Revenue Officer effective January 1, 2024, as well as the EVP of Operations. I would ask Johnny to join us now for the Q&A, and I'll turn it over to the operator to instruct you how to queue for questions. Thank you. We will now be conducting a question-and-answer session. In the interest of time, we ask that you please limit yourself to one question. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove yourself from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Once again, that's star one if you wish to ask a question at this time. One moment please while we begin. Once again, it's star one if you wish to ask a question today. We did have a question come from John Tanwanteng from CJS Securities. John, your line is live. Hi, good afternoon. It's Pete Lukas for John. I guess, start, just, in terms of the VA rollout, how much do you think you can gain from that plan next year on a growth revenue basis or however you want to define it? How should we think about that? Yeah, that's something we'd like to be able to know as well. As I mentioned in my opening remarks, although I gave some directional guidance for next year, this is clearly not the formal guidance, nor is it a budget. As John noted in his comments, and we had a very substantive meeting back in late August with not only Cognosante, the VA, and their various representatives. Here we sit in almost mid-November, and there still is a plan being worked through in terms of exactly how the rollout will proceed. And if I had to put it into two buckets, the initial phase that we discussed last quarter that concluded with the 40 sites, was done on a site basis, and the philosophy was that you would take each individual unit, call it a clinic, hospital, et cetera, and you would convert everything within that facility from what they were currently doing to ECFax. Now, that's not the way we would generally roll out a large-scale corporate enterprise. What has occurred in this sort of next phase that we have been rolling out is, and, and John noted this, is we are rolling out more facilities, but not necessarily taking all the pieces at a moment in time. And this is an important distinction because there are layers of methods by which fax can be sent and received within an organization. To give you some idea, there are individual numbers, point-to-point communications. There's faxes that travel inbound versus outbound. Some may be on servers, some may be associated with multifunction devices, of which there can be a variety. Think HP, Ricoh, Canon, Lexmark, Brother, et cetera. There are applications where you can fax from the application or it can be received in. So it's a nontrivial exercise to think about taking an organization or an office and converting everything they do, because likely they use all of these formats, and converting them all. So typically, what we would do is we would go in order, and the order would be generally how you can get the most users on a platform quickly, and also where there's the most concentration of traffic. I think as, as John noted in his remarks, there is an alignment here between the VA's objectives, Cognosante's objectives, and our objectives, which is more usage, more users, even if it's not necessarily a complete facility that transitions over at a moment in time. Having said that, we're still working through with Cognosante and the VA, what that exactly means and what a rollout going forward looks like. So it's a lengthy answer to let you know that it's very much of a work in progress. What we can say is that there's very little revenue in 2023, what we booked to date, and we're likely to book in the remaining 50-60 days of the year. So we do believe there will be a substantial uptick of a very small base in 2023. But even amongst ourselves, there's some range of what that number could be. My own, my own belief and view is it should be seven digits, but where it is in the seven-digit range is very much a question, I think, yet to be answered. And you know, obviously, we will refine that number and when we release our 2024 guidance in conjunction with the Q4 call, we'll have a more explicit, I think, view on that. Very helpful. Thanks. I'll jump back in the queue. Thank you. Once again, it's star one if you wish to ask a question today. The next question is coming from Fatima Boolani from Citi. Fatima, your line is live. Hey, good afternoon, guys. This is Mark on for Fatima. Thanks for taking our questions. Maybe one for Johnny. Understand it's still early days and, you know, early in the process before you get into the CRO role, but, you know, when you take on the CRO role, you know, any sort of early points you can share of your plans there? Should we maybe expect changes in sales incentives or go-to-market initiatives? And then any sort of, you know, color around areas of upside or downside risk, as you're going to 2024, aside from the, you know, obvious macro headwinds? Thanks. Yeah. Hi. Thank you. Yeah, good question. I think we've, we've started that process earlier this year with the go-to-market realignment. And I had the opportunity on the last earnings call to take everybody through our continuum of customers and how we are migrating our sales motion to meet our customers on their buying motion to be more flexible in the market. And I think we're going to continue on that road. As John mentioned in the remarks, we have started the e-commerce, you know, channel for the corporate space. That's proven to be a successful program, so we're going to continue down that road. So the one thing will definitely be, you know, that alignment with our customer's buying motion, and you know, continuing that realignment of our go-to-market sales and marketing teams. And the other thing will be obviously, you know, continuing to analyze our existing customer base, and doubling down on the, you know, verticals that are most successful for us today, primarily that being the healthcare space, right? We're seeing a lot of growth in that area. Scott talked about it in his opening remarks that it's, you know, more than 50% of our corporate revenue by now. So we're going to continue down that road and double down on those verticals. Great. Thank you. And then maybe just, you know, one for Scott or Jim. You know, as you guys think going into 2024, you know, any sort of guidance on capital allocation strategy or changes there? Good to see the optionality on the debt side, but, you know, what, what's sort of the, you know, priority here given the, you know, macro headwinds? Yeah, and we have a related question that came by email, but I'll answer your question first, and then there's a derivative of that question that came by email, which I'll also address. So we were... Just to bring everybody up to speed who hasn't followed the company since the spin, as I noted in the opening remarks, we were limited in our capital allocation strategies to this point in only being able to obviously invest in the company, repurchase our equity securities, or do M&A. We did a little bit of M&A very early on in acquiring Summit, but that's not really been the focus of the company, as you know. So most of our capital allocation has been allocated to repurchasing stock, which we've done fairly consistently, and of course, banking cash. Now our attention shifts somewhat in that we do have a maturity coming up in a little under three years. Those will be the 6% notes due October 15, 2026, and then two years later, the $500 million of 6.5%. Given that we've crossed the 2-year threshold of the spin, we now have flexibility of buying the securities. Now, in the case of the 6.5%, they're non-called. In the case of the 6%, they're callable, but at a 103 price, and because of the movement in interest rates, both securities trade below par. A little unclear exactly the spot price. The bonds are not quite as liquid as the stock, but I think it's safe to say the 6.5s are in the mid-80s, and the 6s, which have the nearer term maturity, are closer to the mid-90s. And so we will be looking, the board authorized a $200 million repurchase program over the next 3 years. I, I would note that it is opportunistic, so don't be looking for a tender tomorrow at, you know, some spot price. Likely, we will spend some time looking at what can be done in the open market, not dissimilar from what we do with our equity buyback program. Clearly, as we look at both our cash balances and prospective free cash flow, we will be, at least over time, allocating, I'd say, a, you know, a meaningful amount of that to debt retirement. What I can't tell you is at the pace at which it will come or whether it will come in dribs and drabs or chunks, because, you know, the state maturity is 3 years away. We want to get the best deal we can on both securities. We will be looking to buy each tranche, but we'll, you know, we'll have to be. I'm sure you'll be asking the question, you'll see it in our Q's in our case, how much we purchase, each quarter. I think if you look out over a 2- to 3-year time frame, you know, it'll be a significant amount of what I'll call the cumulative cash balances. If you take what we have today, you just accumulate cash over the next 2 to 3 years. Obviously, we don't have to retire the 6% notes of maturity. We can't refinance, but we're also cognizant that it's likely to be a higher interest rate environment than when we issued the notes back in the summer, late summer of 2021. So stay tuned. You'll see it. The derivative question, which as I say, it's very hard to answer, is the specific question on free cash flow for 2024. So let's start by where we are in 2023. So we're at $83 million for the nine months, but Q4 is generally not a cash generative quarter. We've just paid $25.5 million of interest on the two tranches of notes. It's also a quarter where we pay estimated tax payments. And then, of course, there's the normal CapEx, et cetera, that will occur in the quarter. So it's likely that we finish the year below the $83 million number, somewhere probably in the mid-$70 million range, in terms of the baseline. As I look forward, I don't know, based on the last answer, how much of the debt we'll repurchase and how much of an arbitrage there will be, because recognize we are earning 5.40 on our cash. So, you know, eliminating the coupon of 6 and 6.5 gives us a little bit of delta, but I don't know how much I'll be able to buy back, the timing, and for that matter, the price. So the way we look at sort of the cash flow in the next year, and once again, these are very rough numbers as budgeting is far from complete. But we would look at just building the cash for the year, earning interest on it, paying the taxes associated with it, and then we should do better than that if, in fact, we are buying debt in and eliminating either a higher coupon and/or getting a discount, which I expect for both. What I think is the most linear relationship from 2023 to 2024 is the reduction in capitalized labor, CapEx for capitalized labor. We expect that to come down at least $7 million year-over-year. That would flow through directly to free cash flow. So when you get all that together, it means we should be somewhere in the low 80s next year. Hopefully, that is a conservative number, and we can do better based on what we do believe will be some EBITDA growth, as well as some repurchases of the debt in the open market, which will give us some incremental leverage against just earning 5.40 on the cash. Great. Thanks, Guy. Next question. Thank you. There were no other questions in queue at this time. I would now like to hand the call back to Scott Turicchi for closing remarks. Great. Thank you, Paul, and, thank you all for joining us today on our Q3 call. We will have the next earnings call, which of course, will be the Q4 call. And as I mentioned at the beginning, we will have a more robust discussion about 2024 guidance. That will be sometime in probably the latter part of February, third week of February of 2024. We do have an upcoming high yield bond conference at the end of this month, courtesy of Bank of America Merrill Lynch. We'll be there. There will be another conference from BTIG that we'll be at on the 20th of November. That's for the equity holders. And then stay tuned for additional press releases for additional conferences, probably more likely at the beginning of next year versus the balance of this year. Of course, if you do have further questions, you can contact any one of us, and we'd be happy to get back to you. Thank you. Thank you. This does conclude today's conference. You may disconnect at this time, and have a wonderful day. Thank you for your participation.